黄芪注射液对比复方丹参注射液治疗心绞痛的系统评价  

Systematic Evaluation on Astragalus Membranceus Injection versus Compound Danshen Injection in Treatment of Angina Pectoris

作　　者：黄媛[1] 占美[1] 吴逢波[1] 吴斌[1] 徐珽[1] 

机构地区：[1]四川大学华西医院药剂科,四川成都610041

出　　处：《中国药业》2013年第12期61-64,共4页China Pharmaceuticals

摘　　要：目的系统评价黄芪注射液对比复方丹参注射液治疗心绞痛的疗效和安全性。方法计算机检索Cochrane图书馆、EMbase、PubMed、科学引文索引(SCI)数据库、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、中文科技期刊全文数据库(维普)。按纳入与排除标准选择试验、提取资料,并根据Cochrane手册对纳入的随机对照试验(RCT)进行方法学质量评价,采用RevMan 5.1.6软件对数据进行Meta分析。结果纳入9个RCT,共计839例患者。Meta分析结果显示,黄芪注射液治疗组在总有效率[RR=1.19,95%CI(1.08,1.31),P=0.000 4]、临床症状[RR=1.23,95%CI(1.14,1.33),P<0.000 01]和心电图[RR=1.31,95%CI(1.18,1.45),P<0.000 01]有效率方面均优于复方丹参注射液对照组,且差异具有统计学意义。同时,黄芪注射液治疗组不良反应更少[RR=0.17,95%CI(0.03,0.94),P=0.04]。结论现有临床研究显示,黄芪注射液治疗心绞痛的疗效优于复方丹参注射液且安全性更高。但由于纳入的研究证据强度不高且样本量较小,可能影响到结果的可靠性,结论有待更多设计严谨的大样本、多中心随机对照试验予以验证。Objective To systematically evaluate the efficacy and safety of Astragalus Membranceus Injection versus Compound Danshen Injection in the treatment of angina pectoris. Methods Cochrane Library,EBase,PubMed,SCI,CBM,CNKI and VIP were retrieved by computer. According to the predefined inclusion and exclusion criteria,the trials were screened and the data were extracted. Then includ- ed Randomized Controlled Trials （RCT） were performed the methodological quality evaluation based on the Coehrane Handbook and the data were conducted the recta-analysis by using the RevMan software （version 5.1.6）. Results 9 RCTs involving 839 patients were included. The meta- analysis results showed that the Astragalus Membraneeus Injection group was superior to the Compound Dan- shen Injection group in the total effective rate [ RR = 1.19,95% CI （1.08,1.31）, P = 0. 000 4] ,clinical symptoms [ RR = 1.23,95% CI （1.14,1.33）,P 〈 0.000 01] and electrocardiogram effective rate [RR=1.31,95% CI （1.18,1.45）,P 〈 0.000 01].The differences between two groups had statistical significance. In addition, less adverse reactions were found in the Astragalus Membranceus Injection group [ RR =0. 17,95% CI （0. 03,0.94）, P ：0. 04]. Conclusion The existing clinical studies reveal that Astragalus Membranceus In- jection has better efficacy and higher safety in treating angina peetoris than Compound Danshen Injection. However,the evidence intensi- ty of the included studies is not high and the sample size is relatively small, which may affect the result reliability, the conclusion needs to be confirmed by more precisely designed multi- center RCTs with large samples.

关 键 词：冠心病 心绞痛 黄芪注射液 复方丹参注射液 META分析 系统评价 

分 类 号：R285.6[医药卫生—中药学] R286[医药卫生—中医学]